These findings suggested that BCVA (logMAR) (OR: 0.02; 95% CI: 0.00–0.45; p = 0.013), HF (OR: 0.11; 95% CI: 0.01–0.95; p = 0.045), and type 2 MNV (OR: 0.08; 95% CI: 0.01–0.88; p = 0.039) were independent risk factors for the development of subretinal fibrosis in nAMD patients following anti-VEGF therapy (Table 5). This evidence concerns the gene VEGFA and hydrops fetalis.